Inflammatory Bowel Disease Therapeutics (IBD) is a chronic relapsing inflammatory disorder of the GI (gastrointestinal) tract. It is immune mediated and has a relapsing cascade which thereby requires lifelong treatment as well as diagnosis. IBD leads to a continuous structural as well as functional damage to the GI tract.The IBD therapeutics market is expected to experience a significant amount of growth on account of increase in the cases of inflammatory bowel diseases across the world; which are triggered by some agents like bacteria, viruses and antigens. Rising demand of anti-inflammatory drugs and certain strong pipeline of IBD drugs also contributes to the Inflammatory Bowel Disease Therapeutics market growth in future.Inflammatory Bowel Disease Therapeutics Market was valued at US$ 21.7 Billion in 2024 and is projected to grow at a CAGR of 3.60% to reach US$ 21.7 Billion by 2034.

The report “Inflammatory Bowel Disease Therapeutics Market, By Indication (Ulcerative Colitis and Crohn's Disease), By Drug Class (Non-Steroidal Anti-inflammatory drugs (NSAIDs), Anti-inflammatory Biologics, and Corticosteroids), By Type of Molecule (Small Molecules and Biologics), By Drug Form (Solid and Liquid), By Route of Administration (Parenteral and Oral), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034”

Key Highlights:

• In March 2020, Celltrion Healthcare (in Europe) launched ‘Remsima SC’ to treat U.C. and Chrohn’s Disease. Remsima is the formulation of biosimilar infliximab which was also developed by Celltrion. It helps in the neutralizing of tumor necrosis factor-alpha which in turn slows down the disease progression.

• In March, 2023, Abbvie announced top-line results of drug named “Risankizumab (SKYRIZI)” which is a prescribed medication given to patients with severe to moderate Crohn’s disease (in adults). It met all the primary and secondary endpoints in a phase 3 clinical trial which was conducted for Ulcerative Colitis. A significant number of patients treated with this drug were seen with an achievement of a histologic-endoscopic mucosal improvement at week 12 compared to those receiving placebo.

Analyst View:

IBD has been a well-known emerging disease across the world. The constant increase AND rate of prevalence of Crohn’s disease (C.D.) and Ulcerative colitis is the key reason which is leading to the growth of the IBD therapeutics market.  The increase in the use and approval of biologics and pipeline products is expected to push the market growth over the forecast period. Presence of major players, government initiatives in improving healthcare services is expected to foster the demand for Inflammatory Bowel Disease Therapeutics market growth in future.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Inflammatory Bowel Disease Therapeutics Market, By Indication (Ulcerative Colitis and Crohn's Disease), By Drug Class (Non-Steroidal Anti-inflammatory drugs (NSAIDs), Anti-inflammatory Biologics, and Corticosteroids), By Type of Molecule (Small Molecules and Biologics), By Drug Form (Solid and Liquid), By Route of Administration (Parenteral and Oral), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034”

Key Market Insights from the report:

Inflammatory Bowel Disease Therapeutics Market was valued at US$ 21.8 billion in 2024 and is projected to grow at a CAGR of 3.8% to reach US$ 30.7 billion by 2034. The Inflammatory Bowel Disease Therapeutics market is segmented based on Indication, Drug Class,   Type of molecule, Drug Form, Route of Administration and Region.

• Based on Indication, Inflammatory Bowel Disease Therapeutics market is classified into Ulcerative Colitis and Crohn’s Disease.
• Based on Drug class, Inflammatory Bowel Disease Therapeutics market is segmented into Non-Steroidal Anti-inflammatory drugs (NSAIDs), Anti-inflammatory Biologics, and Corticosteroids
• Based on Type of Molecule, Inflammatory Bowel Disease Therapeutics market is segmented into Small Molecules and Biologics.
• By Drug Form, the Inflammatory Bowel Disease Therapeutics market is segmented into Solid and Liquid.
• By Route of Administration, Inflammatory Bowel Disease Therapeutics market is segmented into Parenteral and Oral.
• By Region Inflammatory Bowel Disease Therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Competitive Landscape & their strategies of Inflammatory Bowel Disease Therapeutics market:

The prominent players operating in the Inflammatory Bowel Disease Therapeutics market includes, Abbvie, Inc., Janssen Biotech Inc., GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG., Biogen Idec, Inc., Cosmo Pharmaceuticals SpA, ChemoCentryx, Inc., Falk Pharma GmbH and Eisai Co, Ltd.

To know more

Contact Us:

Sales

Prophecy Market Insights

 U.S.  1 860 531 2574

RoW: 917775049802

Email- sales@prophecymarketinsights.com

Website- www.prophecymarketinsights.com

Blog- www.prophecyjournals.com